FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FA

Food Allergy Clinical Trial

Official title:

The Use of Exhaled Nitric Oxide as a Predictive Marker of Allergic Reactions to Oral Food Challenge and Clinical Response of Omalizumab Treatment in Subjects With Multiple Food Allergies

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06437171
• Other study ID #: ML45389
• Status: Recruiting
• Phase: Phase 4
• Start date: May 2024
• Est. completion date: December 2025

Study information

• Verified date: May 2024
• Source: AAADRS Clinical Research Center
• Contact: Miguel Lanz, MD
• Phone: 3054440441
• Email: MJLANZMD[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase IV, open-label, single-center study to evaluate the change in FeNO as a marker of clinical response to OMA in participants with multiple FA.

Description:

This is a Phase IV, open-label, single-center study to evaluate the change in FeNO as a marker of clinical response to OMA in participants with multiple FA. Twenty (20) participants will be enrolled over a 9-month enrollment period from an allergy and asthma medical specialty clinic. Should the participant meet all eligibility criteria, then following the Screening Period, the participant will be dosed with OMA and asked to continue to follow their food avoidance regimen. Participants will return to the clinic every two weeks for 16-weeks, and then every 2 or 4-weeks (depending on dosing) for the remaining 36-weeks, for a total of 52-weeks. Primary endpoint analyses will occur at Week 16 and Week 52. Description of XOLAIR treatment schedule: Omalizumab will be dosed according to the OUtMATCH Study dosing. Patients will be monitored for acute hypersensitivity reactions for at least 61 minutes after the end of the injection. Epinephrine and parenteral diphenhydramine must be readily available for immediate use if required to treat a hypersensitivity reaction; site personnel must be able to detect and treat such reactions. Patients with severe hypersensitivity reactions (e.g., stridor, angioedema, life-threatening change in vital signs) must be withdrawn from study treatment. All adverse events of systemic hypersensitivity reactions or anaphylactoid or anaphylaxis reactions must be reported within 24 hours to the Sponsor.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: December 2025
• Est. primary completion date: July 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years and older

Eligibility

Inclusion Criteria:

• Patients must meet the following criteria for study entry:
• Able and willing to provide written informed consent from patient and parent or guardian and to comply with the study protocol.
• Age 6 years of age or older at Visit 1
• Documented history of food allergy to one or more of the following foods based on

SPT performed at baseline visit:

• peanut
• milk
• egg
• tree nuts (Walnut/Pecan, Cashew/Pistachio, Almond, Hazelnut, Brazil nut)

Exclusion Criteria:

• Patients who meet any of the following criteria will be excluded from study entry:
• Diagnosis of asthma requiring maintenance medication, including inhaled steroids, leukotriene modifiers, LABA/ICS, biologics medications (Intermittent asthma [Step 1] is allowed and defined according to the 2020 NAEPP guidelines (as 'asthma requiring only prn SABA use) and FEV1 < 80% of predicted normal.
• Diagnosis of nasal polyps, cystic fibrosis or any respiratory condition that will skew normally occurring FeNO levels
• FeNO (measured in ppb) is lower than a value expected for the age, height, and gender of the participant or inability to perform respiratory collection maneuver
• Systemic steroids, leukotriene modifiers, or nasal steroids for any cause/diagnosis within 4 weeks of baseline
• Biologic use, for any diagnosis, within five half-lives of Screening
• Antibiotic use, systemic/oral/intramuscular, for any cause/diagnosis within 2 weeks of baseline
• Active smoker, cigarette, cigar, vape, recreational, and/or prior 10 pack year history
• Participant weight or IgE levels outside of the dosing table for OMA
• Known history of anaphylaxis/hypersensitivity to OMA
• Any medical condition that is serious or unstable that in the opinion of the PI could confound the study results and/or interfere with subject participation or adherence
• Pregnant or breastfeeding, or intending to become pregnant during the study or within 60 days after the last dose of OMA
• Women of childbearing potential must have a negative serum pregnancy test result during the screening period

Related Conditions & MeSH terms

• Food Allergy
• Food Hypersensitivity
• Hypersensitivity

Intervention

Biological:
• Omalizumab
Omalizumab dose and frequency based on baseline subject weight and total IgE

Locations

Country	Name	City	State
United States	AAADRS Clinical Research Center	Coral Gables	Florida

Sponsors (1)

Lead Sponsor	Collaborator
AAADRS Clinical Research Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	FeNO change from baseline to week 52	biomarker	1 year
Secondary	Time to change from baseline FeNO during OFC	biomarker	at baseline and at week 16